argenx (ARGX) Competitors

argenx (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Which has higher valuation and earnings, ARGX or SNY?

Sanofi has higher revenue and earnings than argenx. Sanofi is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$2.58B	13.69	-$295.05M	$16.21	35.68
Sanofi	$45.17B	2.96	$6.02B	$2.80	18.89

Does the MarketBeat Community believe in ARGX or SNY?

argenx received 611 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 67.52% of users gave argenx an outperform vote while only 61.18% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
argenx	Outperform Votes 663 67.52%	Underperform Votes 319 32.48%
Sanofi	Outperform Votes 52 61.18%	Underperform Votes 33 38.82%

Which has more risk & volatility, ARGX or SNY?

argenx has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Do analysts prefer ARGX or SNY?

argenx currently has a consensus target price of $698.11, suggesting a potential upside of 20.72%. Sanofi has a consensus target price of $63.33, suggesting a potential upside of 19.75%. Given argenx's higher probable upside, equities research analysts clearly believe argenx is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	0 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	3.04
Sanofi	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.14

Is ARGX or SNY more profitable?

Sanofi has a net margin of 12.77% compared to argenx's net margin of -2.11%. Sanofi's return on equity of 25.61% beat argenx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenx	-2.11%	-1.45%	-1.29%
Sanofi	12.77%	25.61%	14.72%

Does the media favor ARGX or SNY?

In the previous week, Sanofi had 13 more articles in the media than argenx. MarketBeat recorded 42 mentions for Sanofi and 29 mentions for argenx. argenx's average media sentiment score of 1.17 beat Sanofi's score of 1.04 indicating that argenx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenx	18 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	23 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of ARGX or SNY?

60.3% of argenx shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 2.4% of argenx shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

argenx beats Sanofi on 10 of the 19 factors compared between the two stocks.